Literature DB >> 14508078

mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic.

Paul B Fisher1, Rahul V Gopalkrishnan, Sunil Chada, Rajagopal Ramesh, Elizabeth A Grimm, Myrna R Rosenfeld, David T Curiel, Paul Dent.   

Abstract

An obstacle to effective gene-based cancer therapies is the limited number of cancer-specific growth suppressing and apoptosis-inducing genes. Using a differentiation induction subtraction hybridization (DISH) approach with human melanoma cells, melanoma differentiation associated (mda) genes were isolated that display elevated expression as a function of irreversible growth arrest, cancer reversion and terminal differentiation. This screening paradigm resulted in the cloning of mda-7 in the context of terminal differentiation of human melanoma cells. Based on its structure, chromosomal location, sequence homology and cytokine-like properties, mda-7 has now been renamed IL-24 and classified as a member of the expanding IL-10 cytokine gene family. Expression of mda-7/IL-24 inversely correlates with melanoma progression and administration of mda-7/IL-24 by means of a replication incompetent adenovirus, Ad.mda-7, results in growth suppression and apoptosis in melanoma cells as well as in a broad-spectrum of additional cancer cell types. In contrast, Ad.mda-7 does not elicit deleterious effects in normal cells, including those of epithelial, fibroblast, astrocyte, melanocyte or endothelial origin. Based on these distinctive properties and anti-tumor and anti-angiogenic activities in human tumor xenograft animal models, mda-7/IL-24 has now entered the clinical arena. A Phase I/II clinical trial in patients with advanced carcinomas involving intratumoral administration of mda-7/IL-24 [using a replication incompetent adenovirus; ING241 (Ad.mda-7)] has documented that this gene is safe and well tolerated by patients and a single virus injection elicits apoptosis in a majority of the tumor. Current data suggests that mda-7/IL-24 may function as a dual-acting cytokine in which its normal physiological functions may be related to specific aspects of the immune system and over-expression culminates in cancer-specific apoptosis. This review will provide a prospectus of our current understanding of mda-7/IL-24.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508078

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  67 in total

Review 1.  Structure and function of interleukin-22 and other members of the interleukin-10 family.

Authors:  Daniela Barretto Barbosa Trivella; José Ribamar Ferreira-Júnior; Laure Dumoutier; Jean-Christophe Renauld; Igor Polikarpov
Journal:  Cell Mol Life Sci       Date:  2010-05-08       Impact factor: 9.261

2.  IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells.

Authors:  Emily Y Jen; Nancy J Poindexter; Elizabeth S Farnsworth; Elizabeth A Grimm
Journal:  Melanoma Res       Date:  2012-02       Impact factor: 3.599

3.  Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma.

Authors:  Hossein A Hamed; Adly Yacoub; Margaret A Park; Patrick J Eulitt; Rupesh Dash; Devanand Sarkar; Igor P Dmitriev; Maciej S Lesniak; Khalid Shah; Steven Grant; David T Curiel; Paul B Fisher; Paul Dent
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

Review 4.  Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma.

Authors:  Paul B Fisher; Devanand Sarkar; Irina V Lebedeva; Luni Emdad; Pankaj Gupta; Moira Sauane; Zao-zhong Su; Steven Grant; Paul Dent; David T Curiel; Neil Senzer; John Nemunaitis
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-23       Impact factor: 4.219

Review 5.  Immunomodulation in leukemia: cellular aspects of anti-leukemic properties.

Authors:  M Maleknia; A Valizadeh; S M S Pezeshki; N Saki
Journal:  Clin Transl Oncol       Date:  2019-05-24       Impact factor: 3.405

Review 6.  Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases.

Authors:  Mitchell E Menezes; Praveen Bhoopathi; Anjan K Pradhan; Luni Emdad; Swadesh K Das; Chunqing Guo; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

7.  RGD-IL-24, a novel tumor-targeted fusion cytokine: expression, purification and functional evaluation.

Authors:  Bin Xiao; Wei Li; Jun Yang; Gang Guo; Xu-Hu Mao; Quan-Ming Zou
Journal:  Mol Biotechnol       Date:  2008-10-25       Impact factor: 2.695

8.  mda-7/IL-24 Mediates Cancer Cell-Specific Death via Regulation of miR-221 and the Beclin-1 Axis.

Authors:  Anjan K Pradhan; Sarmistha Talukdar; Praveen Bhoopathi; Xue-Ning Shen; Luni Emdad; Swadesh K Das; Devanand Sarkar; Paul B Fisher
Journal:  Cancer Res       Date:  2016-12-09       Impact factor: 12.701

9.  Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells.

Authors:  Adly Yacoub; Margaret A Park; Pankaj Gupta; Mohammed Rahmani; Guo Zhang; Hossein Hamed; David Hanna; Devanand Sarkar; Irina V Lebedeva; Luni Emdad; Moira Sauane; Nicollaq Vozhilla; Sarah Spiegel; Costas Koumenis; Martin Graf; David T Curiel; Steven Grant; Paul B Fisher; Paul Dent
Journal:  Mol Cancer Ther       Date:  2008-02       Impact factor: 6.261

10.  Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach.

Authors:  Adelaide Greco; Altomare Di Benedetto; Candace M Howard; Sarah Kelly; Rounak Nande; Yulia Dementieva; Michele Miranda; Arturo Brunetti; Marco Salvatore; Luigi Claudio; Devanand Sarkar; Paul Dent; David T Curiel; Paul B Fisher; Pier P Claudio
Journal:  Mol Ther       Date:  2009-11-03       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.